Aurinia nets $52 mln to develop treatment for lupus nephritis
Aurinia Pharmaceuticals Inc (TSX-V: AUP) has completed a US$52 million private placement. The deal was led by venBio, New Enterprise Associates, Redmile Group, RA Capital Management, Great Point Partners and Apple Tree Partners, with the participation of existing investors Lumira Capital, ILJIN Life Science and Difference Capital. Lumira, Difference Capital and ILJIN in 2013 helped finance Aurinia's merger with Isotechnika Pharma Inc. The Edmonton-based company intends to use the new funds for the clinical and non-clinical development of its lead drug candidate, a therapy for treating lupus nephritis. Aurinia's current leadership team includes former senior managers of Aspreva Pharmaceuticals Corp, which was acquired in 2008.
18 February 2014•6 mins read
